

Allan S Jaffe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7747364/publications.pdf>

Version: 2024-02-01

333
papers

43,555
citations

6233

80
h-index

2171

202
g-index

340
all docs

340
docs citations

340
times ranked

30810
citing authors

#	ARTICLE	IF	CITATIONS
1	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755
2	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
3	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
4	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
5	Third universal definition of myocardial infarction. <i>Nature Reviews Cardiology</i> , 2012, 9, 620-633.	6.1	2,615
6	Fourth Universal Definition of Myocardial Infarction (2018). <i>Journal of the American College of Cardiology</i> , 2018, 72, 2231-2264.	1.2	2,285
7	Fourth Universal Definition of Myocardial Infarction (2018). <i>Circulation</i> , 2018, 138, e618-e651.	1.6	1,858
8	Biomarkers in Acute Cardiac Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1-11.	1.2	1,289
9	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
10	Analytical Validation of a High-Sensitivity Cardiac Troponin T Assay. <i>Clinical Chemistry</i> , 2010, 56, 254-261.	1.5	926
11	Case Definitions for Acute Coronary Heart Disease in Epidemiology and Clinical Research Studies. <i>Circulation</i> , 2003, 108, 2543-2549.	1.6	719
12	How to use high-sensitivity cardiac troponins in acute cardiac care. <i>European Heart Journal</i> , 2012, 33, 2252-2257.	1.0	666
13	It's Time for a Change to a Troponin Standard. <i>Circulation</i> , 2000, 102, 1216-1220.	1.6	584
14	Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1642.	3.8	579
15	Clinical characteristics and Thrombolysis In Myocardial Infarction frame counts in women with transient left ventricular apical ballooning syndrome. <i>American Journal of Cardiology</i> , 2004, 94, 343-346.	0.7	546
16	Diagnosis of Perioperative Myocardial Infarction with Measurement of Cardiac Troponin I. <i>New England Journal of Medicine</i> , 1994, 330, 670-674.	13.9	535
17	Recommendations for the use of cardiac troponin measurement in acute cardiac care. <i>European Heart Journal</i> , 2010, 31, 2197-2204.	1.0	533
18	Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination. <i>Annals of Internal Medicine</i> , 2002, 137, 563.	2.0	522

#	ARTICLE	IF	CITATIONS
19	Troponin: the biomarker of choice for the detection of cardiac injury. <i>Cmaj</i> , 2005, 173, 1191-1202.	0.9	509
20	Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. <i>Archives of General Psychiatry</i> , 2005, 62, 792.	13.8	469
21	Perioperative Myocardial Infarction. <i>Circulation</i> , 2009, 119, 2936-2944.	1.6	396
22	Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2005, 51, 810-824.	1.5	385
23	European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials. <i>American Heart Journal</i> , 2002, 144, 981-986.	1.2	376
24	Diastolic dysfunction and mortality in severe sepsis and septic shock. <i>European Heart Journal</i> , 2012, 33, 895-903.	1.0	352
25	Major depressive disorder in coronary artery disease. <i>American Journal of Cardiology</i> , 1987, 60, 1273-1275.	0.7	337
26	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2018, 64, 645-655.	1.5	327
27	Rapid Exclusion of Acute Myocardial Infarction in Patients With Undetectable Troponin Using a High-Sensitivity Assay. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1332-1339.	1.2	325
28	Cardiac Troponin for Assessment of Myocardial Injury in COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1244-1258.	1.2	322
29	Third Universal Definition of Myocardial Infarction. <i>Global Heart</i> , 2012, 7, 275.	0.9	309
30	Regional Systems of Care to Optimize Timeliness of Reperfusion Therapy for ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2007, 116, 729-736.	1.6	299
31	Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care. <i>Clinical Chemistry</i> , 2017, 63, 73-81.	1.5	277
32	Prognostic Influence of Elevated Values of Cardiac Troponin I in Patients With Unstable Angina. <i>Circulation</i> , 1997, 95, 2053-2059.	1.6	277
33	Diseased Skeletal Muscle. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1819-1824.	1.2	244
34	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Use of Cardiac Troponin and B-Type Natriuretic Peptide or N-Terminal proB-Type Natriuretic Peptide for Etiologies Other than Acute Coronary Syndromes and Heart Failure. <i>Clinical Chemistry</i> , 2007, 53, 2086-2096.	1.5	239
35	Fourth Universal Definition of Myocardial Infarction (2018). , 2018, 13, 305-338.		237
36	Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. <i>European Heart Journal</i> , 2012, 33, 2001-2006.	1.0	233

#	ARTICLE	IF	CITATIONS
37	Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. <i>American Heart Journal</i> , 2000, 140, 917-927.	1.2	232
38	Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection. <i>Annals of Internal Medicine</i> , 2017, 166, 715.	2.0	231
39	IFCC educational materials on selected analytical and clinical applications of high sensitivity cardiac troponin assays. <i>Clinical Biochemistry</i> , 2015, 48, 201-203.	0.8	224
40	Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1846-1860.	1.2	199
41	National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: Analytical Issues for Biochemical Markers of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2007, 53, 547-551.	1.5	188
42	Troponin Elevation in Severe Sepsis and Septic Shock. <i>Critical Care Medicine</i> , 2014, 42, 790-800.	0.4	182
43	Quality Specifications for B-Type Natriuretic Peptide Assays. <i>Clinical Chemistry</i> , 2005, 51, 486-493.	1.5	181
44	Assessing the Requirement for the 6-Hour Interval between Specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. <i>Clinical Chemistry</i> , 2006, 52, 812-818.	1.5	179
45	B-Type Natriuretic Peptide Clinical Activation in Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2016-2025.	1.2	172
46	Significance of Periprocedural Myonecrosis on Outcomes After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 10-19.	1.4	165
47	Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury. <i>Clinical Chemistry</i> , 2009, 55, 573-577.	1.5	165
48	Cardiac Magnetic Resonance Imaging Study for Quantification of Infarct Size Comparing Directly Serial Versus Single Time-Point Measurements of Cardiac Troponin T. <i>Journal of the American College of Cardiology</i> , 2008, 51, 307-314.	1.2	162
49	Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 249-257.	1.6	161
50	Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1781-1791.	1.2	156
51	Copeptin Helps in the Early Detection of Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 150-160.	1.2	153
52	Plasma Ceramides. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1933-1939.	1.1	147
53	High-sensitivity cardiac troponin T in prediction and diagnosis of myocardial infarction and long-term mortality after noncardiac surgery. <i>American Heart Journal</i> , 2013, 166, 325-332.e1.	1.2	142
54	Biological and Analytical Variability of a Novel High-Sensitivity Cardiac Troponin T Assay. <i>Clinical Chemistry</i> , 2010, 56, 1086-1090.	1.5	140

#	ARTICLE	IF	CITATIONS
55	The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. <i>American Heart Journal</i> , 2008, 155, 208-214.	1.2	137
56	Sensitive Troponin Assay and the Classification of Myocardial Infarction. <i>American Journal of Medicine</i> , 2015, 128, 493-501.e3.	0.6	134
57	Redefinition of Myocardial Infarction. <i>Circulation</i> , 2006, 114, 790-797.	1.6	133
58	Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. <i>Critical Care Medicine</i> , 2008, 36, 759-765.	0.4	131
59	Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. <i>European Heart Journal</i> , 2006, 27, 1061-1069.	1.0	129
60	Preparing the United States for High-Sensitivity Cardiac Troponin Assays. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1753-1758.	1.2	129
61	Value of Cardiac Troponin I Cutoff Concentrations below the 99th Percentile for Clinical Decision-Making. <i>Clinical Chemistry</i> , 2009, 55, 85-92.	1.5	127
62	Cross-Reactivity of BNP, NT-proBNP, and proBNP in Commercial BNP and NT-proBNP Assays: Preliminary Observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. <i>Clinical Chemistry</i> , 2008, 54, 619-621.	1.5	124
63	Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial Infarction. <i>Clinical Chemistry</i> , 2005, 51, 2198-2200.	1.5	123
64	Being Rational about (Im)precision: A Statement from the Biochemistry Subcommittee of the Joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation Task Force for the Definition of Myocardial Infarction. <i>Clinical Chemistry</i> , 2010, 56, 941-943.	1.5	120
65	Defining High-Sensitivity Cardiac Troponin Concentrations in the Community. <i>Clinical Chemistry</i> , 2013, 59, 1099-1107.	1.5	118
66	Social support and prognosis in patients at increased psychosocial risk recovering from myocardial infarction.. <i>Health Psychology</i> , 2007, 26, 418-427.	1.3	112
67	Practical Implementation of the Guidelines for Unstable Angina/Non-“ST-Segment Elevation Myocardial Infarction in the Emergency Department. <i>Circulation</i> , 2005, 111, 2699-2710.	1.6	109
68	Comparison of Mass Spectrometry and Clinical Assay Measurements of Circulating Fragments of B-Type Natriuretic Peptide in Patients With Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 355-360.	1.6	108
69	Effectiveness of EDACS Versus ADAPT Accelerated Diagnostic Pathways for Chest Pain: A Pragmatic Randomized Controlled Trial Embedded Within Practice. <i>Annals of Emergency Medicine</i> , 2016, 68, 93-102.e1.	0.3	107
70	Requiem for a Heavyweight. <i>Circulation</i> , 2008, 118, 2200-2206.	1.6	104
71	Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1059-1077.	1.2	103
72	Effect of population selection on 99th percentile values for a high sensitivity cardiac troponin I and T assays. <i>Clinical Biochemistry</i> , 2013, 46, 1636-1643.	0.8	100

#	ARTICLE	IF	CITATIONS
73	High-Sensitivity Cardiac Troponin T Concentrations below the Limit of Detection to Exclude Acute Myocardial Infarction: A Prospective Evaluation. <i>Clinical Chemistry</i> , 2015, 61, 983-989.	1.5	97
74	Possible mechanisms behind cardiac troponin elevations. <i>Biomarkers</i> , 2018, 23, 725-734.	0.9	95
75	Extracorporeal Membrane Oxygenation Use in Acute Myocardial Infarction in the United States, 2000 to 2014. <i>Circulation: Heart Failure</i> , 2019, 12, e005929.	1.6	91
76	Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. <i>American Heart Journal</i> , 2015, 169, 6-16.e6.	1.2	89
77	Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population. <i>Clinical Chemistry</i> , 2009, 55, 1809-1815.	1.5	88
78	Changes in comorbidities, diagnoses, therapies and outcomes in a contemporary cardiac intensive care unit population. <i>American Heart Journal</i> , 2019, 215, 12-19.	1.2	87
79	Soluble ST2 Analytical Considerations. <i>American Journal of Cardiology</i> , 2015, 115, 8B-21B.	0.7	86
80	Lipoprotein-Associated Phospholipase A2 and Prognosis After Myocardial Infarction in the Community. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2517-2522.	1.1	85
81	Depression and five year survival following acute myocardial infarction: A prospective study. <i>Journal of Affective Disorders</i> , 2008, 109, 133-138.	2.0	79
82	Incidence, Trends, and Outcomes of Type 2 Myocardial Infarction in a Community Cohort. <i>Circulation</i> , 2020, 141, 454-463.	1.6	77
83	Global Adoption of High-Sensitivity Cardiac Troponins and the Universal Definition of Myocardial Infarction. <i>Clinical Chemistry</i> , 2019, 65, 484-489.	1.5	76
84	Recommended guidelines for in-hospital cardiac monitoring of adults for detection of arrhythmia. <i>Journal of the American College of Cardiology</i> , 1991, 18, 1431-1433.	1.2	71
85	Myocardial Dysfunction in Severe Sepsis and Septic Shock. <i>Chest</i> , 2015, 148, 93-102.	0.4	71
86	Acute respiratory failure and mechanical ventilation in cardiogenic shock complicating acute myocardial infarction in the USA, 2000-2014. <i>Annals of Intensive Care</i> , 2019, 9, 96.	2.2	71
87	Sex Disparities in the Management and Outcomes of Cardiogenic Shock Complicating Acute Myocardial Infarction in the Young. <i>Circulation: Heart Failure</i> , 2020, 13, e007154.	1.6	71
88	Cardiac Involvement in Patients With Acute Neurologic Disease. <i>Archives of Internal Medicine</i> , 2000, 160, 3153.	4.3	70
89	Rapid rule out of acute myocardial infarction: novel biomarker-based strategies. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 218-222.	0.4	70
90	Elevations in Cardiac Troponin Measurements: False False-Positives: The Real Truth. <i>Cardiovascular Toxicology</i> , 2001, 1, 087-092.	1.1	69

#	ARTICLE	IF	CITATIONS
91	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	1.0	69
92	Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. <i>European Heart Journal</i> , 2021, 42, 323-334.	1.0	68
93	Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations. <i>Clinical Chemistry</i> , 2007, 53, 220-227.	1.5	67
94	Elevated Cardiac Troponin T Levels in Critically Ill Patients with Sepsis. <i>American Journal of Medicine</i> , 2013, 126, 1114-1121.	0.6	67
95	Prediction of medical morbidity and mortality after acute myocardial infarction in patients at increased psychosocial risk in the Enhancing Recovery in Coronary Heart Disease Patients (ENRICH) study. <i>American Heart Journal</i> , 2006, 152, 126-135.	1.2	66
96	History of Depression and Survival After Acute Myocardial Infarction. <i>Psychosomatic Medicine</i> , 2009, 71, 253-259.	1.3	66
97	Short- and Long-term Individual Variation in Cardiac Troponin in Patients with Stable Coronary Artery Disease. <i>Clinical Chemistry</i> , 2013, 59, 401-409.	1.5	66
98	What to do when you question cardiac troponin values. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 577-586.	0.4	66
99	Regional Variation in the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock in the United States. <i>Circulation: Heart Failure</i> , 2020, 13, e006661.	1.6	64
100	Diagnostic accuracy of clinical prediction rules to exclude acute coronary syndrome in the emergency department setting: a systematic review. <i>Canadian Journal of Emergency Medicine</i> , 2008, 10, 373-382.	0.5	62
101	Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding*. <i>Critical Care Medicine</i> , 2009, 37, 140-147.	0.4	62
102	Validation of a Proposed Novel Equation for Estimating LDL Cholesterol. <i>Clinical Chemistry</i> , 2014, 60, 1519-1523.	1.5	62
103	Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective. <i>American Journal of Medicine</i> , 2017, 130, 1112.e9-1112.e15.	0.6	61
104	Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department. <i>Clinical Biochemistry</i> , 2018, 60, 11-16.	0.8	60
105	Temporal trends and outcomes of prolonged invasive mechanical ventilation and tracheostomy use in acute myocardial infarction with cardiogenic shock in the United States. <i>International Journal of Cardiology</i> , 2019, 285, 6-10.	0.8	60
106	Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. <i>American Journal of Cardiology</i> , 2002, 90, 634-636.	0.7	59
107	Specificity of B-Type Natriuretic Peptide Assays: Cross-Reactivity with Different BNP, NT-proBNP, and proBNP Peptides. <i>Clinical Chemistry</i> , 2017, 63, 351-358.	1.5	58
108	Brain Natriuretic Peptide Levels in Constrictive Pericarditis and Restrictive Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1489-1491.	1.2	56

#	ARTICLE	IF	CITATIONS
109	Troponin Release—Reversible or Irreversible Injury? Should We Care?. <i>Clinical Chemistry</i> , 2012, 58, 148-150.	1.5	56
110	The 10 commandments of troponin, with special reference to high sensitivity assays. <i>Heart</i> , 2011, 97, 940-946.	1.2	54
111	Using High-sensitivity Troponin T: The Importance of the Proper Gold Standard. <i>American Journal of Medicine</i> , 2013, 126, 709-717.	0.6	54
112	Pulmonary artery catheter use in acute myocardial infarction—cardiogenic shock. <i>ESC Heart Failure</i> , 2020, 7, 1234-1245.	1.4	54
113	Sex disparities in acute kidney injury complicating acute myocardial infarction with cardiogenic shock. <i>ESC Heart Failure</i> , 2019, 6, 874-877.	1.4	53
114	Improving Prediction of Postoperative Myocardial Infarction With High-Sensitivity Cardiac Troponin T and NT-proBNP. <i>Anesthesia and Analgesia</i> , 2017, 124, 398-405.	1.1	51
115	Temporal trends, predictors, and outcomes of acute kidney injury and hemodialysis use in acute myocardial infarction-related cardiogenic shock. <i>PLoS ONE</i> , 2019, 14, e0222894.	1.1	51
116	Acute Coronary Syndrome Biomarkers. <i>Circulation</i> , 2004, 110, 104-106.	1.6	50
117	Timing of Peak Troponin T and Creatine Kinase-MB Elevations After Percutaneous Coronary Intervention. <i>Chest</i> , 2004, 125, 275-280.	0.4	50
118	Usefulness of Detectable Levels of Troponin, Below the 99th Percentile of the Normal Range, as a Clue to the Presence of Underlying Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2007, 100, 764-769.	0.7	50
119	Weight Change after Myocardial Infarction—the Enhancing Recovery in Coronary Heart Disease patients (ENRICHD) Experience. <i>American Heart Journal</i> , 2008, 155, 478-484.	1.2	50
120	Significance of Elevated Cardiac Troponin T Levels in Critically Ill Patients with Acute Respiratory Disease. <i>American Journal of Medicine</i> , 2010, 123, 1049-1058.	0.6	49
121	High-Sensitivity Troponin I and Amino-Terminal Pro-B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population. <i>Clinical Chemistry</i> , 2014, 60, 1225-1233.	1.5	49
122	Third Universal Definition of Myocardial Infarction. <i>Clinical Biochemistry</i> , 2013, 46, 1-4.	0.8	48
123	Biomarker Responses during and after Treatment with Nesiritide Infusion in Patients with Decompensated Chronic Heart Failure. <i>Clinical Chemistry</i> , 2005, 51, 569-577.	1.5	47
124	Using High-Sensitivity Cardiac Troponin T for Acute Cardiac Care. <i>American Journal of Medicine</i> , 2017, 130, 1358-1365.e1.	0.6	47
125	Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Heart</i> , 2014, 100, 424-432.	1.2	46
126	Eliminating Creatine Kinase—Myocardial Band Testing in Suspected Acute Coronary Syndrome. <i>JAMA Internal Medicine</i> , 2017, 177, 1508.	2.6	46

#	ARTICLE	IF	CITATIONS
127	Soluble ST2 and galectin-3 in pediatric patients without heart failure. <i>Clinical Biochemistry</i> , 2015, 48, 1337-1340.	0.8	45
128	Lipoprotein-associated Phospholipase A 2 : Review and Recommendation of a Clinical Cut Point for Adults. <i>Preventive Cardiology</i> , 2006, 9, 138-143.	1.1	44
129	Clinical implications of the change of cardiac troponin I levels in patients with acute chest pain – An evaluation with respect to the Universal Definition of Myocardial Infarction. <i>Clinica Chimica Acta</i> , 2011, 412, 91-97.	0.5	44
130	Early vs. delayed in-hospital cardiac arrest complicating ST-elevation myocardial infarction receiving primary percutaneous coronary intervention. <i>Resuscitation</i> , 2020, 148, 242-250.	1.3	44
131	Cardiovascular biomarkers in patients with COVID-19. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 310-319.	0.4	44
132	Heart Rate Turbulence, Depression, and Survival After Acute Myocardial Infarction. <i>Psychosomatic Medicine</i> , 2007, 69, 4-9.	1.3	43
133	Development of an optimized multimarker strategy for early risk assessment of patients with acute coronary syndromes. <i>Clinica Chimica Acta</i> , 2008, 393, 103-109.	0.5	42
134	Relationship of MRI-Determined Infarct Size and cTnI Measurements in Patients with ST-Elevation Myocardial Infarction. <i>Clinical Chemistry</i> , 2008, 54, 617-619.	1.5	42
135	Lower Rather Than Higher Levels of B-Type Natriuretic Peptides (NT-pro-BNP and BNP) Predict Short-Term Mortality in End-Stage Heart Failure Patients Treated With Nesiritide. <i>American Journal of Cardiology</i> , 2005, 96, 837-841.	0.7	41
136	Myocardial injury in severe COVID-19 infection. <i>European Heart Journal</i> , 2020, 41, 2080-2082.	1.0	38
137	High-Sensitivity Cardiac Troponin for the Diagnosis of Patients with Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2017, 19, 92.	1.3	37
138	Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol $\geq 70\text{ mg/dL}$ compared with a novel low-density lipoprotein estimation method. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1065-1072.	0.6	37
139	Determinants and prognostic implications of Cardiac Troponin T measured by a sensitive assay in Type 2 Diabetes Mellitus. <i>Cardiovascular Diabetology</i> , 2010, 9, 52.	2.7	36
140	Increasing Cardiac Troponin Changes Measured by a Research High-Sensitivity Troponin I Assay: Absolute vs Percentage Changes and Long-Term Outcomes in a Chest Pain Cohort. <i>Clinical Chemistry</i> , 2010, 56, 1902-1904.	1.5	36
141	Why all the struggle about CK-MB and PCI?. <i>European Heart Journal</i> , 2012, 33, 1046-1048.	1.0	36
142	Sex and Gender Disparities in the Management and Outcomes of Acute Myocardial Infarction – Cardiogenic Shock in Older Adults. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1916-1927.	1.4	36
143	Importance of Low Concentrations of Cardiac Troponins. <i>Clinical Chemistry</i> , 2006, 52, 1614-1615.	1.5	35
144	High-Sensitivity Cardiac Troponin: Hype, Help, and Reality. <i>Clinical Chemistry</i> , 2010, 56, 342-344.	1.5	35

#	ARTICLE	IF	CITATIONS
145	Sex-Specific Associations of Established and Emerging Cardiac Biomarkers with All-Cause Mortality in Older Adults: The ActiFE Study. <i>Clinical Chemistry</i> , 2015, 61, 389-399.	1.5	35
146	Natriuretic Peptides and Analytical Barriers. <i>Clinical Chemistry</i> , 2017, 63, 50-58.	1.5	34
147	Troponinâ€”Past, Present, and Future. <i>Current Problems in Cardiology</i> , 2012, 37, 209-228.	1.1	33
148	Reliability of Calculated Low-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2015, 116, 538-540.	0.7	33
149	Detectable High-Sensitivity Cardiac Troponin within the Population Reference Interval Conveys High 5-Year Cardiovascular Risk: An Observational Study. <i>Clinical Chemistry</i> , 2018, 64, 1044-1053.	1.5	33
150	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 633-640.	1.4	33
151	Clinical Impact of High-Sensitivity Cardiac Troponin T Implementation in theÂCommunity. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3160-3170.	1.2	33
152	Biologic Variation of a Novel Cardiac Troponin I Assay. <i>Clinical Chemistry</i> , 2011, 57, 1080-1081.	1.5	32
153	Long-time quality assessment of the Elecsys Troponin T hs assay. <i>Clinical Biochemistry</i> , 2013, 46, 1055-1057.	0.8	32
154	Editorâ€™s Choice-Rule-in of acute myocardial infarction: Focus on troponin. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 212-217.	0.4	32
155	ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome). <i>Circulation</i> , 2018, 137, 354-363.	1.6	32
156	Atherosclerotic Cardiovascular Disease RiskÂStratification Based on Measurements of Troponin and Coronary Artery Calcium. <i>Journal of the American College of Cardiology</i> , 2020, 76, 357-370.	1.2	32
157	Troponina cardiaca ultrasensible: de la teorÃa a la prÃctica clÃnica. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 687-691.	0.6	31
158	Prognostic Value of Serial Measurements of Soluble Suppression of Tumorigenicity 2 and Galectin-3 in Ambulatory Patients With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 249-255.	0.7	31
159	Comparison of high-sensitivity cardiac troponin I and T for the prediction of cardiac complications after non-cardiac surgery. <i>American Heart Journal</i> , 2018, 203, 67-73.	1.2	31
160	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. <i>Circulation</i> , 2020, 142, 1532-1544.	1.6	31
161	In search for the Holy Grail: Suggestions for studies to define delta changes to diagnose or exclude acute myocardial infarction: a position paper from the study group on biomarkers of the Acute Cardiovascular Care Association. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 313-316.	0.4	30
162	Natriuretic Peptides to Predict Short-Term Mortality in Patients With Sepsis: A Systematic Review and Meta-analysis. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 50-64.	1.2	30

#	ARTICLE	IF	CITATIONS
163	Ruling-In Myocardial Injury and Ruling-Out Myocardial Infarction With the European Society of Cardiology 1-Hour Algorithm. <i>Circulation</i> , 2016, 134, 1542-1545.	1.6	29
164	Sex-specific 99th percentiles derived from the AACC Universal Sample Bank for the Roche Gen 5 cTnT assay: Comorbidities and statistical methods influence derivation of reference limits. <i>Clinical Biochemistry</i> , 2017, 50, 1073-1077.	0.8	29
165	Complications in Patients with Acute Myocardial Infarction Supported with Extracorporeal Membrane Oxygenation. <i>Journal of Clinical Medicine</i> , 2020, 9, 839.	1.0	29
166	Ceramide Scores Predict Cardiovascular Risk in the Community. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1558-1569.	1.1	29
167	Prognostic Value of Cardiac Troponin T After Myocardial Infarction: A Contemporary Community Experience. <i>Mayo Clinic Proceedings</i> , 2012, 87, 247-254.	1.4	28
168	Analytical performance of an immunoassay to measure proenkephalin. <i>Clinical Biochemistry</i> , 2018, 58, 72-77.	0.8	28
169	High-Sensitivity Cardiac Troponin I Levels in Normal and Hypertensive Pregnancy. <i>American Journal of Medicine</i> , 2019, 132, 362-366.	0.6	28
170	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2021, 67, 730-735.	1.5	28
171	High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and Risk Stratification in COVID-19. <i>Clinical Chemistry</i> , 2021, 67, 1080-1089.	1.5	28
172	Biomarker-based risk prediction in the community. <i>European Journal of Heart Failure</i> , 2016, 18, 1342-1350.	2.9	27
173	Long-term prognosis of patients with clinical unstable angina pectoris without elevation of creatine kinase but with elevation of cardiac troponin i levels. <i>American Journal of Cardiology</i> , 2002, 90, 875-878.	0.7	26
174	PAPP-A as a marker of increased long-term risk in patients with chest pain. <i>Clinical Biochemistry</i> , 2009, 42, 1012-1018.	0.8	26
175	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally? Sometimes earlier may not be better Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. <i>European Heart Journal</i> , 2016, 37, 3316-3323.	1.0	26
176	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. <i>American Heart Journal</i> , 2017, 190, 135-139.	1.2	26
177	The Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2020, 141, 1434-1436.	1.6	26
178	Analytical Considerations in Deriving 99th Percentile Upper Reference Limits for High-Sensitivity Cardiac Troponin Assays: Educational Recommendations from the IFCC Committee on Clinical Application of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2022, 68, 1022-1030.	1.5	26
179	Advantages of the lipoprotein-associated phospholipase A2 activity assay. <i>Clinical Biochemistry</i> , 2016, 49, 172-175.	0.8	25
180	Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction. <i>Clinical Chemistry</i> , 2017, 63, 1163-1165.	1.5	25

#	ARTICLE	IF	CITATIONS
181	Weekend Effect in the Management and Outcomes of Acute Myocardial Infarction in the United States, 2000-2016. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 362-372.	1.2	25
182	Ceramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors. <i>Clinica Chimica Acta</i> , 2020, 511, 138-142.	0.5	25
183	Effect of myocardial ischemia on cardiac troponin I and T. <i>American Journal of Cardiology</i> , 2002, 89, 224-226.	0.7	24
184	Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Naïve Emergency Department Patients. <i>Clinical Chemistry</i> , 2006, 52, 2028-2035.	1.5	24
185	Multi-center validation of the Response Biomedical Corporation RAMPÂ® NT-proBNP assay with comparison to the Roche Diagnostics GmbH ElecsysÂ® proBNP assay. <i>Clinica Chimica Acta</i> , 2007, 386, 20-24.	0.5	23
186	High-sensitivity Cardiac Troponin: From Theory to Clinical Practice. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 687-691.	0.4	23
187	Unraveling N-Terminal Pro-B-Type Natriuretic Peptide: Another Piece to a Very Complex Puzzle in Heart Failure Patients. <i>Clinical Chemistry</i> , 2015, 61, 1016-1018.	1.5	23
188	ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care: A fond farewell at the retirement of CKMB. <i>European Heart Journal</i> , 2021, 42, 2260-2264.	1.0	23
189	Myocardial Infarction with Normal Coronary Arteries: A Role for MRI?. <i>Clinical Chemistry</i> , 2007, 53, 995-996.	1.5	22
190	The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. <i>Medical Clinics of North America</i> , 2007, 91, 657-681.	1.1	22
191	Screening for kidney disease in vascular patients: SCreening for Occult REnal Disease (SCORED) experience. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2452-2457.	0.4	22
192	Ninety-Minute vs 3-h Performance of High-Sensitivity Cardiac Troponin Assays for Predicting Hospitalization for Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2013, 59, 1407-1410.	1.5	22
193	High-Sensitivity Cardiac Troponin Assays: Isn't It Time for Equality?. <i>Clinical Chemistry</i> , 2014, 60, 7-9.	1.5	22
194	The prognostic impact of periprocedural myocardial infarction and injury. <i>European Heart Journal</i> , 2018, 39, 1110-1112.	1.0	22
195	99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. <i>Clinical Chemistry</i> , 2020, 66, 1167-1180.	1.5	22
196	Natriuretic Peptides in Heart Failure. <i>Clinical Chemistry</i> , 2014, 60, 1040-1046.	1.5	21
197	Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. <i>Clinical Chemistry</i> , 2016, 62, 824-830.	1.5	21
198	Biomarkers in heart failure: the importance of inconvenient details. <i>ESC Heart Failure</i> , 2016, 3, 3-10.	1.4	21

#	ARTICLE	IF	CITATIONS
199	High-Sensitivity Cardiac Troponin T Improves the Diagnosis of Perioperative MI. <i>Anesthesia and Analgesia</i> , 2017, 125, 1455-1462.	1.1	21
200	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019, 65, 1221-1227.	1.5	21
201	Cardiovascular biomarkers: The state of the art in 2006. <i>Clinica Chimica Acta</i> , 2007, 381, 9-13.	0.5	20
202	Decision Support Tool for Early Differential Diagnosis of Acute Lung Injury and Cardiogenic Pulmonary Edema in Medical Critically Ill Patients. <i>Chest</i> , 2012, 141, 43-50.	0.4	20
203	Prognostic Value of N-Terminal Pro-form B-Type Natriuretic Peptide in Patients With Moderate Aortic Stenosis. <i>American Journal of Cardiology</i> , 2020, 125, 1566-1570.	0.7	20
204	High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: An initial foray. <i>Clinica Chimica Acta</i> , 2010, 411, 812-817.	0.5	19
205	Temporal Trends, Predictors, and Outcomes of Acute Ischemic Stroke in Acute Myocardial Infarction in the United States. <i>Journal of the American Heart Association</i> , 2021, 10, e017693.	1.6	19
206	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. <i>Revista Española De Cardiología</i> , 2013, 66, 132.e1-132.e15.	0.6	18
207	Men are different than women: It's true for cardiac troponin too. <i>Clinical Biochemistry</i> , 2014, 47, 867-868.	0.8	18
208	TRAPID or Trapped?. <i>Annals of Emergency Medicine</i> , 2016, 68, 88-91.	0.3	18
209	Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	18
210	Using high sensitivity cardiac troponin values in patients with SARS-CoV-2 infection (COVID-19): The Padova experience. <i>Clinical Biochemistry</i> , 2021, 90, 8-14.	0.8	18
211	Improving the 510(k) FDA Process for Cardiac Troponin Assays: In Search of Common Ground. <i>Clinical Chemistry</i> , 2014, 60, 1273-1275.	1.5	17
212	Fundamental Concepts of Effective Troponin Use: Important Principles for Internists. <i>American Journal of Medicine</i> , 2015, 128, 111-119.	0.6	17
213	Use of Biomarkers in the Emergency Department and Chest Pain Unit. <i>Cardiology Clinics</i> , 2005, 23, 453-465.	0.9	16
214	Elevations of troponin in patients with epileptic seizures? What do they mean?. <i>Clinical Cardiology</i> , 2006, 29, 325-326.	0.7	15
215	From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 714-721.	0.3	15
216	Epidemiological Trends in the Timing of In-Hospital Death in Acute Myocardial Infarction-Cardiogenic Shock in the United States. <i>Journal of Clinical Medicine</i> , 2020, 9, 2094.	1.0	15

#	ARTICLE	IF	CITATIONS
217	Implementing High-Sensitivity Cardiac Troponin T in a US Regional Healthcare System. <i>Circulation</i> , 2020, 141, 1937-1939.	1.6	15
218	Plasma Ceramide Levels Are Elevated in Patients With Early Coronary Atherosclerosis and Endothelial Dysfunction. <i>Journal of the American Heart Association</i> , 2022, 11, e022852.	1.6	15
219	Rapid Exclusion of Acute Myocardial Injury and Infarction With a Single High-Sensitivity Cardiac Troponin T in the Emergency Department: A Multicenter United States Evaluation. <i>Circulation</i> , 2022, 145, 1708-1719.	1.6	15
220	Defining the Optimal Cardiac Troponin T Threshold for Predicting Death Caused by Periprocedural Myocardial Infarction After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 533-542.	1.4	14
221	Nocturnal patterns of heart rate and the risk of mortality after acute myocardial infarction. <i>American Heart Journal</i> , 2014, 168, 117-125.	1.2	14
222	Measuring the contribution of Lp(a) cholesterol towards LDL-C interpretation. <i>Clinical Biochemistry</i> , 2020, 86, 45-51.	0.8	14
223	“Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. <i>Clinica Chimica Acta</i> , 2008, 387, 133-138.	0.5	13
224	Implications of the universal definition of myocardial infarction. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, 678-679.	3.3	13
225	High Sensitivity Troponin in Chest Pain and Acute Coronary Syndromes. A Step Forward?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2010, 63, 763-769.	0.4	13
226	Troponin Elevations After Electroconvulsive Therapy: The Need for Caution. <i>American Journal of Medicine</i> , 2011, 124, 229-234.	0.6	13
227	Acute Coronary Syndromes in the Community. <i>Mayo Clinic Proceedings</i> , 2015, 90, 597-605.	1.4	13
228	Lipid Biomarkers for Risk Assessment in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2017, 19, 48.	1.3	13
229	Intervention to Reduce Inappropriate Ionized Calcium Ordering Practices: A Quality-Improvement Project. , 2015, 19, 49-51.		13
230	Key Issues in the Developing Synergism between Cardiovascular Imaging and Biomarkers. <i>Clinical Chemistry</i> , 2008, 54, 1432-1442.	1.5	12
231	Clinical differences between total PAPP-A and measurements specific for the products of free PAPP-A activity in patients with stable cardiovascular disease. <i>Clinical Biochemistry</i> , 2014, 47, 177-183.	0.8	12
232	Identification of myocardial injury in the emergency setting. <i>Clinical Biochemistry</i> , 2010, 43, 539-544.	0.8	11
233	Biochemical Validation of Patient-Reported Symptom Onset Time in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 778-787.	1.1	11
234	ST-segment Elevation, Myocardial Injury, and Suspected or Confirmed COVID-19 Patients: Diagnostic and Treatment Uncertainties. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1107-1111.	1.4	11

#	ARTICLE	IF	CITATIONS
235	Racial Disparities in the Utilization and Outcomes of Temporary Mechanical Circulatory Support for Acute Myocardial Infarction-Cardiogenic Shock. <i>Journal of Clinical Medicine</i> , 2021, 10, 1459.	1.0	11
236	Sex disparities in management and outcomes of cardiac arrest complicating acute myocardial infarction in the United States. <i>Resuscitation</i> , 2022, 172, 92-100.	1.3	11
237	Nighttime Heart Rate and Survival in Depressed Patients Post Acute Myocardial Infarction. <i>Psychosomatic Medicine</i> , 2008, 70, 757-763.	1.3	10
238	Early Trends in N-Terminal Pro-Brain Natriuretic Peptide Values After Left Ventricular Assist Device Implantation for Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 1257-1263.	0.7	10
239	Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the <scp>CHOPIN</scp> Trial. <i>Academic Emergency Medicine</i> , 2015, 22, 554-563.	0.8	10
240	Unwinding the Interaction of Natriuretic Peptides and Natriuretic Peptide Receptor-1. <i>Journal of the American College of Cardiology</i> , 2015, 65, 666-667.	1.2	10
241	Pre-analytical considerations in biomarker research: focus on cardiovascular disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1747-1760.	1.4	10
242	Aborted myocardial infarction: Is it real in the troponin era?. <i>American Heart Journal</i> , 2009, 157, 636-641.	1.2	9
243	Evaluation of Patients With Possible Cardiac Chest Pain. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2099-2100.	1.2	9
244	Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. <i>Clinical Chemistry</i> , 2017, 63, 37-44.	1.5	9
245	Biomarkers of coagulation and fibrinolysis in acute myocardial infarction: a joint position paper of the Association for Acute Cardiovascular Care and the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 343-355.	0.4	9
246	Can Natriuretic Peptides be Used to Guide Therapy?. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 208-16.	0.7	9
247	Bedside Multimarker Testing for Risk Stratification in Chest Pain Units: The Chest Pain Evaluation by Creatine Kinase-MB, Myoglobin, and Troponin I (CHECKMATE) Study. <i>Circulation</i> , 2001, 104, .	1.6	8
248	Elevation of cardiac troponin T in patients with amyotrophic lateral sclerosis. <i>Acta Neurologica Belgica</i> , 2016, 116, 557-564.	0.5	8
249	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromes—The COPACS Study. <i>American Journal of Medicine</i> , 2016, 129, 105-114.	0.6	8
250	Comparing analytical outliers and the percent of emergency department patients with results above the 99th percentile upper reference limit for 2 conventional and one high sensitivity troponin assay. <i>Clinical Biochemistry</i> , 2018, 53, 104-109.	0.8	8
251	Science Moves Slowly. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1550-1552.	1.2	8
252	Sex-Specific 99th Percentile URLs for Cardiac Troponin Assays—Their Time Has Come. <i>Clinical Chemistry</i> , 2021, 67, 197-200.	1.5	8

#	ARTICLE	IF	CITATIONS
253	Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study. <i>American Heart Journal</i> , 2022, 244, 54-65.	1.2	8
254	Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol. <i>Journal of the American Heart Association</i> , 2022, 11, e023136.	1.6	8
255	Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. <i>Clinical Biochemistry</i> , 2014, 47, 155-157.	0.8	7
256	Troponin T as a Predictor of End-Stage Renal Disease and All-Cause Death in African Americans and Whites From Hypertensive Families. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1482-1491.	1.4	7
257	Release of cardiac troponin using a high sensitivity assay after exercise: Type 2 acute myocardial infarction?. <i>Clinica Chimica Acta</i> , 2015, 446, 6-8.	0.5	7
258	High-Sensitivity Cardiac Troponin and Primary Prevention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2729-2732.	1.2	7
259	In Reply. <i>Clinical Chemistry</i> , 2017, 63, 1167-1170.	1.5	7
260	Intracranial Hemorrhage Complicating Acute Myocardial Infarction: An 18-Year National Study of Temporal Trends, Predictors, and Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2717.	1.0	7
261	Prediction of Death After Noncardiac Surgery: Potential Advantage of Using High-Sensitivity Troponin T as a Continuous Variable. <i>Journal of the American Heart Association</i> , 2021, 10, e018008.	1.6	7
262	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. <i>Biomarkers</i> , 2021, 26, 639-646.	0.9	7
263	Analytical and Clinical Considerations in Implementing the Roche Elecsys Troponin T Gen 5 STAT Assay. <i>American Journal of Clinical Pathology</i> , 2021, 156, 1121-1129.	0.4	7
264	An enhanced ceramide-based approach for primary prevention of atherosclerotic events. <i>European Heart Journal Open</i> , 2021, 1, .	0.9	7
265	The clinical impact of the universal diagnosis of myocardial infarction. <i>Clinical Chemistry and Laboratory Medicine</i> , 2008, 46, 1485-8.	1.4	6
266	High-sensitivity troponin: where are we now and where do we go from here?. <i>Biomarkers in Medicine</i> , 2014, 8, 1021-1032.	0.6	6
267	Using Biomarkers to Guide Heart Failure Therapy. <i>Clinical Chemistry</i> , 2017, 63, 954-957.	1.5	6
268	1-h High-Sensitivity Troponin Rule-Out and Rule-In Approach. <i>Journal of the American College of Cardiology</i> , 2018, 72, 633-635.	1.2	6
269	Influence of primary payer status on the management and outcomes of ST-segment elevation myocardial infarction in the United States. <i>PLoS ONE</i> , 2020, 15, e0243810.	1.1	6
270	High Sensitivity Cardiac Troponin Assays - How to Implement them Successfully. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2016, 27, 217-23.	0.7	6

#	ARTICLE	IF	CITATIONS
271	High-Sensitivity Troponin in Patients With Coronary Artery Endothelial Dysfunction. <i>Journal of Invasive Cardiology</i> , 2018, 30, 406-410.	0.4	6
272	Use and Prognostic Implications of Cardiac Troponin in COVID-19. <i>Cardiology Clinics</i> , 2022, 40, 287-300.	0.9	6
273	Major adverse cardiovascular events after diagnosis of myocardial injury and types 1 and 2 myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2022, 11, 546-557.	0.4	6
274	Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
275	Refining Our Criteria. <i>American Journal of Clinical Pathology</i> , 2009, 131, 11-13.	0.4	5
276	The clinical impact of circulating caspase-3 p17 level: a potential new biomarker for myocardial injury and cardiovascular disease. <i>Future Cardiology</i> , 2011, 7, 443-445.	0.5	5
277	Another Unanswerable Question. <i>JACC Basic To Translational Science</i> , 2017, 2, 115-117.	1.9	5
278	Use of High-Sensitivity Cardiac Troponin in Patients With Chronic Comorbidities. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1138-1140.	1.2	5
279	Management and outcomes of uncomplicated ST-segment elevation myocardial infarction patients transferred after fibrinolytic therapy. <i>International Journal of Cardiology</i> , 2020, 321, 54-60.	0.8	5
280	The Gloomy Long-Term Prognosis of Patients With Type 2 Myocardial Infarction or Myocardial Injury. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1014-1016.	1.2	5
281	Return-to-Play Guidelines for Athletes After COVID-19 Infection. <i>JAMA Cardiology</i> , 2021, 6, 479.	3.0	5
282	The Elevated High-Sensitivity Cardiac Troponin T Pilot. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2366-2375.	1.4	5
283	Clinical use of cardiac troponin for acute cardiac care and emerging opportunities in the outpatient setting. <i>Minerva Medica</i> , 2019, 110, 139-156.	0.3	5
284	Prognostic performance of high-sensitivity cardiac troponin T kinetic changes adjusted for elevated admission values and the GRACE score in an unselected emergency department population. <i>Clinica Chimica Acta</i> , 2014, 435, 29-35.	0.5	4
285	Republished: Clinical implications of the Third Universal Definition of Myocardial Infarction. <i>Postgraduate Medical Journal</i> , 2014, 90, 502-510.	0.9	4
286	Biological variability of lipoprotein-associated phospholipase A 2 activity in healthy individuals. <i>Clinical Biochemistry</i> , 2017, 50, 347-349.	0.8	4
287	Clarifying the Proper Definitions for Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1291.	1.2	4
288	Should myocardial infarction type 2 be regarded as two separate entities?. <i>European Heart Journal</i> , 2019, 40, 2810-2812.	1.0	4

#	ARTICLE	IF	CITATIONS
289	It Will Take More Than Better Diagnostics to Improve the Care of Women With ACS. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2044-2046.	1.2	4
290	Acute Myocardial Infarction Due to Fixed Coronary Artery Stenosis From Myocardial Bridging. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 91-93.	0.3	4
291	Revisiting the definition of perioperative myocardial infarction after coronary artery bypass grafting. <i>European Heart Journal</i> , 2022, , .	1.0	4
292	Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008991.	1.6	4
293	Structural Cardiac Abnormalities in Patients with Atrial Fibrillation/Flutter and Myocardial Injury. <i>American Journal of Medicine</i> , 2022, 135, 1488-1496.e5.	0.6	4
294	Interpreting Biomarkers During Percutaneous Coronary Intervention: The Need to Reevaluate Our Approach. <i>Archives of Internal Medicine</i> , 2012, 172, 508.	4.3	3
295	Another Piece to the Troponin Puzzle. <i>Journal of the American College of Cardiology</i> , 2013, 62, 641-642.	1.2	3
296	Can amyotrophic lateral sclerosis chronically elevate troponin T?. <i>Cor Et Vasa</i> , 2015, 57, e320-e322.	0.1	3
297	Letter by Sandoval et al Regarding Article, "Designing a Better Mousetrap: Reflections on the November 28, 2017, US Food and Drug Administration Meeting on Next-Generation High-Sensitivity Cardiac Troponin Assays to Diagnose Myocardial Infarction." <i>Circulation</i> , 2019, 139, 562-563.	1.6	3
298	Beneficial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: pas Ã cause du BNP?. <i>European Journal of Heart Failure</i> , 2019, 21, 609-612.	2.9	3
299	Adjusting the MI Codes Into the Framework of the Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 858-860.	1.2	3
300	B-type natriuretic peptides in heart failure: update on clinical applications and limitations. <i>Biomarkers in Medicine</i> , 2007, 1, 503-512.	0.6	2
301	High-Sensitivity Troponin in the Triage of Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 600-602.	1.9	2
302	Does cardiac rhythm monitoring in patients with elevated troponin levels lead to changes in management?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 545-552.	0.4	2
303	Meta-Analyses and Interpretation of Troponin Values in Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 198-200.	1.9	2
304	Estimating short- and long-term reference change values and index of individuality for tests of platelet function. <i>Clinical Biochemistry</i> , 2019, 74, 54-59.	0.8	2
305	Influence of Human Immunodeficiency Virus Infection on the Management and Outcomes of Acute Myocardial Infarction With Cardiogenic Shock. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 331-339.	0.9	2
306	Our nearly complete diagnostic trip of thousands of steps begets a new trip therapeutically. <i>European Heart Journal</i> , 2020, 41, 2217-2219.	1.0	2

#	ARTICLE	IF	CITATIONS
307	Raising the Bar for Clinical Cardiac Troponin Research Studies and Implementation Science. <i>Circulation</i> , 2021, 143, 2225-2228.	1.6	2
308	<i>Cardiac Function.</i> , 2012, , 1457-1522.		2
309	High-Sensitivity Troponin T Testing for Pediatric Patients in the Emergency Department. <i>Pediatric Cardiology</i> , 2022, 43, 350-359.	0.6	2
310	Fourth Universal Definition of Myocardial Infarction: Will it change how we practice emergency medicine?. <i>Emergencias</i> , 2019, 31, 55-57.	0.6	2
311	Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injury—Opinion from the Front Lines. <i>American Journal of Medicine</i> , 2022, 135, 935-938.	0.6	2
312	Can creatine kinase MB levels predict mortality after cardiac surgery?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005, 2, 280-281.	3.3	1
313	Incidence and significance of elevated lactate in the identification of critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1819-23.	1.4	1
314	Vasospasm and Type 2 AMI?. <i>American Journal of Medicine</i> , 2015, 128, 329-330.	0.6	1
315	Renal Dysfunction: How to Think About That in Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2017, 19, 91.	1.3	1
316	Reply to letter by Trupp et al.. <i>Clinical Biochemistry</i> , 2018, 52, 174.	0.8	1
317	Biomarker and Invasive Hemodynamic Assessment of Cardiac Damage Class in Aortic Stenosis. <i>Structural Heart</i> , 2021, 5, 208-217.	0.2	1
318	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021, 27, 1456-1461.	0.7	1
319	Influence of primary payer status on non-ST-segment elevation myocardial infarction: 18-year retrospective cohort national temporal trends, management and outcomes. <i>Annals of Translational Medicine</i> , 2021, 9, 1075-1075.	0.7	1
320	<i>Biomarkers in Acute Ischemic Heart Disease.</i> , 2011, , 101-112.		1
321	The Biological Variability of Plasma Ceramides in Healthy Subjects. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 863-870.	0.6	1
322	The Costs of Inadequate Data. <i>Academic Emergency Medicine</i> , 2000, 7, 687-688.	0.8	0
323	Reply. <i>Journal of the American College of Cardiology</i> , 2013, 62, 648.	1.2	0
324	Better Ways to Move Ahead. <i>Journal of Cardiac Failure</i> , 2015, 21, 362-363.	0.7	0

#	ARTICLE	IF	CITATIONS
325	MY APPROACH to cardiac troponin elevations in patients with renal disease. Trends in Cardiovascular Medicine, 2015, 25, 655-656.	2.3	0
326	How Good Does It Need to Be? —. Journal of the American College of Cardiology, 2016, 67, 1541-1543.	1.2	0
327	Commentary. Clinical Chemistry, 2017, 63, 48-49.	1.5	0
328	Improving the Specificity of Cardiac Biomarkers—The Early Development of Cardiac Troponin I (cTnl) Assays. Clinical Chemistry, 2018, 64, 609-610.	1.5	0
329	78-Year-Old Woman With Intermittent Chest Pain and Palpitations. Mayo Clinic Proceedings, 2019, 94, e117-e121.	1.4	0
330	High-Sensitivity Troponin: Revealing the Ominous Implications of Myocardial Injury in Critical Illness*. Critical Care Medicine, 2021, 49, 1572-1575.	0.4	0
331	Reply. Journal of the American College of Cardiology, 2021, 78, e149-e150.	1.2	0
332	Biochemical markers of myocardial necrosis. , 2011, , 125-131.		0
333	Professor Giora Landesberg, MD, DSc, MBA, 1954-2021: A Physician and Research Pioneer in Perioperative Myocardial Infarction. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 1254-1257.	0.6	0